{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-26-000554","form_type":"8-K","ticker":"ARTL","cik":"0001621221","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.662651+00:00","generated_at":"2026-05-15T08:50:23.594081+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Artelo expands ART27.13 development for muscle preservation with GLP-1 therapies","bullets":["ART27.13 to be evaluated as companion therapy to prevent muscle loss in patients on GLP-1 receptor agonists for weight reduction.","Preclinical study initiated; provisional patent filed covering use of CB2 agonists with GLP-1 drugs.","Independent research validated ART27.13 as a superagonist among 17 clinically studied CB2 agonists.","Muscle protective effect observed in CAReS trial (cancer cachexia) and preclinical reversal of myotoxicity.","J.P. Morgan projects global incretin market to reach $200B by 2030; ~25M Americans on GLP-1 by 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-26-000554","json":"https://secwatch.observer/filing/0001640334-26-000554.json","markdown":"https://secwatch.observer/filing/0001640334-26-000554.md","text":"https://secwatch.observer/filing/0001640334-26-000554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000554/0001640334-26-000554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000554/artl_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:50:23.594081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0821c4b3f99561217bab637bd98ccb0b0f8b69c4","claim":"ARTELO BIOSCIENCES, INC. entered into Securities Purchase Agreement with Labrys Fund II, L.P. valued at aggregate principal amount of $315,000.00 (effective 2026-03-20).","evidence_excerpt":"On March 20, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of March 20, 2026 (the “Purchase Agreement”), with Labrys Fund II, L.P., a Delaware limited partnership (“Labrys”), pursuant to which the Company issued a 10% promissory note in the aggregate principal amount of $315,000.00, which includes an original issue discount of $15,000.00, for an aggregate purchase price of $300,000.00 (the “Note”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000554/0001640334-26-000554-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Labrys Fund II, L.P."},{"label":"Value","value":"aggregate principal amount of $315,000.00"},{"label":"Effective","value":"2026-03-20"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}